Proteomics International Laboratories (ASX: PIQ) Prepares for Promarker Endo Launch After National Rollout

Aditi Sarkar

23 October 2026 07:58 PM AEDT

Proteomics International Laboratories (ASX: PIQ) Prepares for Promarker Endo Launch After National Rollout

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

National rollout of Promarker D and Promarker Eso to begin on 26 October 2026.
Tests distributed through exclusive pathology partner Healius.
Initial private-pay prices of $495 for Promarker D and $997 for Promarker Eso.
Promarker Endo commercial release targeted for January to March 2027.

Proteomics International Laboratories Ltd (ASX: PIQ) has announced that the national rollout of its Promarker D and Promarker Eso blood tests is scheduled to begin on Monday, 26 October 2026. The rollout will be delivered with Healius Limited (ASX: HLS), the company’s exclusive Australian pathology distribution partner. It follows a controlled market release through the Healius network in Western Australia and the Northern Territory, announced in September 2026.

Rollout Readiness

Field sales teams have completed training on both tests, including their intended clinical uses and how clinicians and patients can access them. Proteomics International and Healius have also agreed joint sales and marketing plans to build clinician awareness, provide education and support appropriate referrals.

Systems and operational processes are expected to go live on 26 October, after which Healius collection centres will accept patients for blood collection and process payments. The tests will initially be available on a private-pay basis at $495 for Promarker D and $997 for Promarker Eso.

Roles of Each Partner

Proteomics International will continue to perform laboratory testing at its NATA-accredited facility and provide clinical reporting, scientific and medical support, and quality and regulatory compliance. Healius will support specimen collection, pathology distribution and clinician engagement through its national network.

CEO and Managing Director David Morris described the national rollout as a significant milestone in bringing the Promarker portfolio to Australian clinicians and patients. Healius Group Executive Anthea Muir said the partnership combines Healius’ collection network and clinician relationships with Proteomics International’s specialist testing capability.

Promarker Endo and Commercial Outlook

On 13 October 2026, Proteomics International announced it had completed refinement and independent validation of the model behind its Promarker Endo blood test for endometriosis. The company expects to make Promarker Endo commercially available in the January to March 2027 quarter, subject to clinical deployment and quality, accreditation and regulatory requirements.

The company said the systems, collection processes and clinician engagement established for the current rollout should support the introduction of Promarker Endo. It noted that, as the Promarker portfolio is at an early stage of commercialisation, revenue under the distribution agreement cannot yet be reliably estimated.

Key Takeaways

The national rollout significantly widens access to Proteomics International’s Promarker D and Promarker Eso tests through Healius’ collection network. As the tests are private-pay and at an early stage, clinician adoption will be the key driver of uptake. Early rollout progress and the planned Promarker Endo launch in early 2027 are the main items to watch.

FAQs

Q: How much do the tests cost?

A:$495 for Promarker D and $997 for Promarker Eso, on a private-pay basis.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.